Voraxaze
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.voraxaze.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Voraxaze
BTG International Inc. specializes in Voraxaze (glucarpidase), a medication designed to significantly reduce plasma methotrexate levels in patients experiencing delayed methotrexate clearance due to acute kidney injury. The product is aimed at both adult and pediatric oncology patients who face severe risks from high-dose methotrexate toxicity. Through early intervention with Voraxaze, the company promotes lower rates of toxicity and mortality associated with methotrexate treatment. The company provides resources for healthcare professionals to better manage methotrexate toxicity and outcomes in cancer care.Explore more
Popular SearchesVoraxazeBtgSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Voraxaze your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Voraxaze recently announced quarterly report
Check out if Voraxaze is spiking on competitors!
Check if Voraxaze has recently received funding, and reach out quickly before it becomes old news!
Voraxaze, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Voraxaze has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Voraxaze had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Voraxaze
Product Launch: Get notified when Voraxaze launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Voraxaze
Compare insights from companies similar to Voraxaze, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Voraxaze
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Voraxaze is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Voraxaze is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Voraxaze.
Voraxaze Tech Stack
A closer look at the technologies used by Voraxaze
Voraxaze News & Media
New economic analysis of Voraxaze® (glucarpidase) in patients with delayed methotrexate
Model simulation shows cost of timely Voraxaze® use is offset by shorter hospital stays and associated with substantially improved clinical outcomes Model simulation shows cost of timely Voraxaze® use is offset by shorter hospital stays and associated with substantially improved clinical outcomesFour Independent Studies of Voraxaze® Published at European Hematology Conference 2022
Vienna, June 09, 2022 (GLOBE NEWSWIRE) -- The European Hematology Association (EHA) Conference published four independent studies of Voraxaze® (glucarpidase) by various investigators for inclusion in its June 2022 EHA Hybrid Congress abstract book and for publication in HemaSphere, EHA’s peer-reviewed, open access journal.Study Underway to Examine the Planned Use of Voraxaze® with Methotrexate in CNS Lymphoma
PHILADELPHIA, April 23, 2020 /PRNewswire/ -- Initial data has been posted online from an investigator initiated pilot study exploring the planned use of Voraxaze® (glucarpidase) administered with repeated doses of methotrexate and rituximab in patients with central nervous system lymphoma...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Voraxaze
Sign Up For FreeTo access detailed company insights
BTG International Inc. specializes in Voraxaze (glucarpidase), a medication designed to significantly reduce plasma methotrexate levels in patients experiencing delayed methotrexate clearance due to acute kidney injury. The product is aimed at both adult and pediatric oncology patients who face severe risks from high-dose methotrexate toxicity. Thr... Read More
